Clinical value of 131I and operation in the treatment of papillary thyroid carcinoma
Zeng Wei
Liang Jiwang
Gao Peng
Abstract：Objective To investigate the clinical value of surgical treatment combined with 131I in the treatment of thyroid papillary carcinoma. Methods 55 cases of papillary thyroid cancer patients were selected from January 2008 to June 2011 in our hospital and were retrospectively analyzed. 55 cases of patients were treated with total thyroidectomy surgical ,postoperative underwent thyroid hormone and 131I radionuclide therapy,The patients were followed up. Results 50 cases of patients received surgical treatment for the first time,5 cases for the second surgery,surgical complications were mainly laryngeal recurrent nerve injury in 9 cases,permanent hoarseness in 2 cases,hypocalcemic seizures in 3 cases, and 14 patients received modified neck lymph node dissection. At 3 months or 6 months after operation,the levels of serum p53,Fas and TNF-a were significantly higher than immediate time after surgery (P < 0.05) and cyclinE protein levels were significantly lower than immediate time after surgery (P < 0.05). There were no difference of serum P53,Fas,TNF-and CyclinE protein levels between at 3 months and 6 months after operation(P>0.05). During 5 years of follow-up, 5 cases were lost,and the 5-year recurrence rate of 4.00%(2/50),including 1 case at 41 months and 1 case at 56 months after operation. And the distant metastasis rate was 2.00%(1/50). Conclusion Operation combined with 131I radionuclide therapy has better clinical results than single treatment, and can reduce CyclinE protein levels and increase serum P53 , Fas and TNF-αlevels.
Keywords：Papillary thyroid carcinomaIsotope131I
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 46-48 )